In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Here's what you need to know about the possible next generation of shots. Moderna's combo flu and COVID vaccine provided a strong immune response in older adults, with levels comparable to getting ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Northwestern University filed a patent infringement ...

If you missed the early fall push for flu and COVID-19 vaccines ... The Pfizer and Moderna shots are formulated against a ...

(Reuters) - Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new ...